AI Summary
Generated by AI for informational purposes only
This eye drop lowers pressure inside the eye and is used to treat glaucoma. It can also be used to help eyelashes grow longer and thicker. It is generally not recommended during pregnancy and should be used with caution while breastfeeding.
Indications
Bimatoprost ophthalmic solution is indicated for the reduction of intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.
Pharmacology
Bimatoprost is a synthetic prostamide analogue with potent ocular hypotensive activity. It selectively mimics the effects of a naturally occurring substance, prostamide. Bimatoprost is believed to lower intraocular pressure (IOP) in humans by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. Timolol Maleate is a nonselective beta-adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant or local anaesthetic (membrane stabilizing) activity. Timolol is thought to work by decreasing the amount of aqueous humor formed in the eye.
Dosage & Administration
Important: Do not take any medication without a doctor's prescription. Self-medication can be dangerous.
The recommended dose is one drop in the affected eye(s) once daily, either in the morning or in the evening. Use at the same time each day.
Interaction
There is not known drug interactions and none well documented.
Contraindications
Contraindicated in patients with hypersensitivity to any component of this medication. Also in patients with bronchospasm, bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, sick sinus syndrome, sino-atrial block, second or third degree atrioventricular block, overt cardiac failure or cardiogenic shock.
Side Effects
No adverse drug reactions (ADR's) specific for Bimatoprost and Timolol combination have been observed in clinical studies. The ADR's have been limited to those for Bimatoprost and Timolol. The majority of ADR's are mild in severity and none were serious, e.g., conjunctival hyperaemia, eye Pruritus, burning sensation, foreign body sensation in the eye, erythema of eyelid, eye pain, photophobia, eye irritation, eyelid oedema, lacrimation increased, growth of eyelashes.
Pregnancy & Lactation
There are no adequate and well controlled studies in pregnant women. Consequently, Bimatoprost should not be used during pregnancy unless clearly necessary. There are no data on the excretion of Bimatoprost into human milk or on the safety of Bimatoprost exposure in infants. Timolol is excreted in human milk and there is potential for adverse reactions in breastfed infants. Bimatoprost should not be used by breast-feeding women.
Precautions & Warnings
Caution should be exercised in treating patients with severe and uncontrolled cardiovascular disease. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked. Patients with active intraocular inflammation, corneal diseases should be treated with caution.
Storage Conditions
Keep away from light and wet place. Store below 30°C temperature. Keep out of reach of children. To prevent contamination of the dropper tip and solution, care should be taken. Don't touch the eyelids, surrounding areas, finger or other surfaces with the dropper tip of the bottle. The bottle should be tightly closed when not in use. Do not use after 4 weeks of first opening.
The information provided on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Always consult a qualified healthcare professional before starting, stopping, or changing any medication.
All brands listed might have copyright or trademark of their respective owners. Listed information may not be up-to-date or accurate. We do not guarantee the availability, quality, price or safety of any medication. Use at your own risk.
